Intel Named Contender for Apple Partnership and 4 Stock Analyses Sparking Chatter
Cubist Pharmaceuticals Inc. (NASDAQ:CBST): Hospira (NYSE:HSP) could possibly apply for FDA approval of its own version of Cubist’s Cubicin, and RBC Capital is convinced that this overhang on Cubist is “addressable.” The firm views Cubist’s fundamentals as being solid, and it keeps its Outperform rating and a $53 price target on the stock.
Francesca’s Holdings Corp (NASDAQ:FRAN): RBC Capital thinks that that the recent weakness in Francesca’s stock was mostly due to concerns regarding the retirement of its relatively young CEO. The firm continues to be upbeat about the new CEO and believes that the company’s business trends have probably continued to be good. The firm keeps its Outperform rating and a $42 price target on the stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Intel Corporation (NASDAQ:INTC): After press reports were released stating that Apple (NASDAQ:AAPL) has begun to consider working with foundries not owned by Samsung, RBC Capital thinks that Intel is in contention to become a foundry partner for Apple. The firm expects total foundry revenue from Apple in 2013 to be approximately $2 billion, and it keeps its Sector Perform rating on Intel stock.
OmniVision Technologies Inc. (NASDAQ:OVTI) reported stronger Q2 results than predicted, influencing RW Baird to expect the company’s gross margin to see a slow rebound, and the firm keeps its Outperform rating.
St. Jude Medical Inc. (NYSE:STJ) estimates have been increased by UBS by 5 percent after the company’s new $1 billion repurchase plan. The firm thinks that the repurchase is 2 to 3 times greater than was expected by investors, and it is a major vote of confidence by the board. Shares have a Buy rating and a $44 price target.
Don’t Miss: Moody’s to H-P: Apple is Eating Your Lunch.